Şunu aradınız:: oestrous (İngilizce - Maltaca)

no influence on the monkey oestrous cycle has been observed.
ma kien osservat l-ebda effett fuq iċ-ċiklu sesswali tax-xadini.

oestrous cycles and fertility were adversely affected in all bazedoxifene- treated female groups.
iċ-ċikli estruwi u l-fertilità kienu affettwati ħażin fil- gruppi kollha ta’ nisa ttrattati b’bazedoxifene.

in females, an effect on the oestrous cycle delayed time to confirmed mating at all doses tested.
fin-nisa, effett fuq iċ-ċiklu estruż dewwem iż-żmien sakemm it-tgħammir ġie kkonfermat fid-dożi kollha ttestjati.

in animal studies, pramipexole affected oestrous cycles and reduced female fertility as expected for a dopamine agonist.
fi studji fuq l-annimali, pramipexole affettwa ċ- ċikli oestrous u naqqas il-fertilità fin-nisa kif mistenni minn agonist ta’ dopamine.

studies in rats indicated that reproductive performance, fertility, oestrous cycling, days between pairing and coitus, and intrauterine survival were unaffected by pegfilgrastim given subcutaneously.
studji fil-frien wera li l-ħila riproduttiva, fertilita, ċiklu ta’ estreus, ġranet bejn tqabbil u coitus, u s-sopravivenza fil-ġuf ma ġewx affettwati bl pegfilgrastim mogħtija taħt il-ġilda.

at high doses (≥450 mg/kg/day) rats exhibited a prolongation of oestrous cycle and a high incidence of irregular cycles.
f’dożi għoljin (≥450 mg/kg/jum) il-firien urew titwil taċ-ċiklu tal-oestrus u inċidenza għolja ta’ ċikli irregolari.

in females, dosages above this were associated with reductions in the overall fertility index, number of pregnancies, number of corpora lutea and implantation sites, as well as changes in the oestrous cycle.
fin-nisa, dożaġġi ogħla minn dan l-ammont ġew assoċjati ma’ tnaqqis fl-indiċi globali tal-fertilità, fin-numru ta’ tqaliet, fin-numru ta’ corpora lutea u siti ta’ impjantazzjoni, kif ukoll ma’ tibdil fiċ-ċiklu oestrous.

following dosing for a longer treatment duration prior to mating (9 weeks) that permitted recovery from the initial effects of rimonabant, no adverse effects were seen on fertility or oestrous cyclicity.
wara li ngħata dożaġġ aktar fit- tul ta 9 ġimgħat, qabel it- tgħammir, li ippermettew l- irkupru mill- effetti inizjali ta ’ ad rimonabant, ma kienx hemm effetti avversi fuq il- fertilità jew fiċ- ċiklu tas- saħħna sesswali.

reductions in oestrous cycles were observed at 50 mg/kg/day, a dose associated with maternal toxicity (body weight loss and reduced food consumption).
tnaqqis fiċ-ċikli estruwi kien osservat f’50 mg/kg/kuljum, doża assoċjata ma’ tossiċità materna (telf fil-piż tal-ġisem u tnaqqis fil-konsum tal-ikel).

female rats receiving duloxetine (45 mg/kg/day) before and during mating and early pregnancy had a decrease in maternal food consumption and body weight, oestrous cycle disruption, decreased live birth indices and progeny survival, and progeny growth retardation at systemic exposure levels estimated to be at the most at maximum clinical exposure (auc).
firien tas-sess femminil li rċevew duloxetine, qabel u waqt li kienu qed jgħamlu s-sess u fil-bidu tat-tqala, kellhom tnaqqis fil-konsum ta' l-ikel matern u fil-piż, diżordni fiċ-ċiklu oestrous, nuqqas fl-indiċi ta' twelid ta' frieħ hajjin u fis-sopravivenza tal-ferħ ta' l- annimal, u dewmien biex jikbru l-frieħ f’livelli ta’ espożizzjoni sistemika, stmata li hija mhux anqas mill-esponiment massimu kliniku (auc).